BVAXF
BioVaxys Technology Corp.
Price Chart
Latest Quote
$0.18
+0.00 (+0.00%)
Current Price
| Previous Close | $0.18 |
| Open | $0.18 |
| Day High | $0.18 |
| Day Low | $0.18 |
| Volume | 1,380 |
Stock Information
Note: Financial values converted from CAD to USD
| Shares Outstanding | 40.65M |
| Total Debt | $96K |
| Cash Equivalents | $3K |
| Net Income | $-4.28M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $7.28M |
| EPS (TTM) | $-0.17 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.35M |
| Income | $-4.28M |
| Book/sh | $-0.09 |
| Cash/sh | $0.00 |
Financial Ratios
| Quick Ratio | 0.10 |
| Current Ratio | 0.28 |
Returns & Margins
| ROA | -152.79% |
Ownership
| Insider Ownership | 8.23% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -1.98 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.14 |
| SMA50 | $0.09 |
| SMA200 | $0.15 |
| RSI | 53.28 |
| ATR | 0.0552 |
| Shares Float | 26.14M |
| Volatility | 1.13 |
| Rel Volume | 0.39 |
Performance History
| Week | +5.36% |
| Month | +221.94% |
| Quarter | +108.87% |
| 6 Months | +17.76% |
| YTD | +4.37% |
| Year | -40.73% |
| 3 Years | -24.63% |
| 5 Years | -90.43% |
| 10 Years | -56.97% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-04 | $0.18 | 25,304 |
| 2026-06-03 | $0.18 | 36,522 |
| 2026-06-02 | $0.17 | 0 |
| 2026-06-01 | $0.17 | 24,327 |
| 2026-05-29 | $0.17 | 20,232 |
| 2026-05-28 | $0.17 | 20,017 |
| 2026-05-27 | $0.17 | 76,952 |
| 2026-05-26 | $0.17 | 66,470 |
| 2026-05-22 | $0.16 | 418,482 |
| 2026-05-21 | $0.12 | 205,588 |
| 2026-05-20 | $0.10 | 64,865 |
| 2026-05-19 | $0.15 | 56,733 |
| 2026-05-18 | $0.16 | 79,118 |
| 2026-05-15 | $0.17 | 57,707 |
| 2026-05-14 | $0.17 | 69,368 |
| 2026-05-13 | $0.12 | 20,609 |
| 2026-05-12 | $0.08 | 7,719 |
| 2026-05-11 | $0.08 | 28,287 |
| 2026-05-08 | $0.06 | 0 |
| 2026-05-07 | $0.06 | 28,171 |
| 2026-05-06 | $0.06 | 157,248 |
| 2026-05-05 | $0.06 | 0 |
About BioVaxys Technology Corp.
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, a formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy. In addition, the company develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health's proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. Further, the company operates HapTenix Platform, a vaccine platform based on the established immunological concept that modifies surface proteins with haptens and T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies triggered by exposure to peanut/tree nuts or eggs and Adiverna LLC to develop mRNA-based Rabies, Leptospirosis, Feline Infectious Peritonitis (FIV) and other mRNA-based vaccines for companion animal veterinary applications. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $3,295,516 | $6,453,188 | $4,081,793 | $6,442,033 |
| Other Income Expense | $-659,265 | $-1,258,977 | $-7,661,422 | $-23,562 |
| Net Non Operating Interest Income Expense | $0 | $24,848 | $15,771 | $7,656 |
| Operating Expense | $3,295,516 | $6,453,188 | $4,081,793 | $6,442,033 |
| Other Operating Expenses | $177,265 | $4,056,836 | $283,866 | $463,357 |
| Selling And Marketing Expense | $422,448 | $0 | $174,298 | $1,719,801 |
| General And Administrative Expense | $2,694,303 | $2,262,620 | $2,660,921 | $3,532,818 |
| Other Non Operating Income Expenses | - | $171,195 | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,954,781 | $-7,687,317 | $-11,727,444 | $-6,457,939 |
| Net Interest Income | $0 | $24,848 | $15,771 | $7,656 |
| Interest Income | $0 | $24,848 | $15,771 | $7,656 |
| Normalized Income | $-3,295,516 | $-6,428,340 | $-4,066,022 | $-6,434,377 |
| Net Income From Continuing And Discontinued Operation | $-3,954,781 | $-7,687,317 | $-11,727,444 | $-6,457,939 |
| Net Income Common Stockholders | $-3,954,781 | $-7,687,317 | $-11,727,444 | $-6,457,939 |
| Net Income | $-3,954,781 | $-7,687,317 | $-11,727,444 | $-6,457,939 |
| Net Income Including Noncontrolling Interests | $-3,954,781 | $-7,687,317 | $-11,727,444 | $-6,457,939 |
| Net Income Continuous Operations | $-3,954,781 | $-7,687,317 | $-11,727,444 | $-6,457,939 |
| Pretax Income | $-3,954,781 | $-7,687,317 | $-11,727,444 | $-6,457,939 |
| Special Income Charges | $-654,908 | $-1,231,452 | $-7,644,931 | $0 |
| Interest Income Non Operating | $0 | $24,848 | $15,771 | $7,656 |
| Operating Income | $-3,295,516 | $-6,453,188 | $-4,081,793 | $-6,442,033 |
| Net Income Discontinuous Operations | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-0.20 | $-0.60 | $-1.20 | $-0.80 |
| Basic EPS | $-0.20 | $-0.60 | $-1.20 | $-0.80 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-2,636,251 | $-5,194,211 | $3,579,629 | $-6,418,471 |
| Total Unusual Items | $-659,265 | $-1,258,977 | $-7,661,422 | $-23,562 |
| Total Unusual Items Excluding Goodwill | $-659,265 | $-1,258,977 | $-7,661,422 | $-23,562 |
| EBITDA (Bullshit earnings) | $-3,295,516 | $-6,453,188 | $-4,081,793 | $-6,442,033 |
| EBIT | $-3,295,516 | $-6,453,188 | $-4,081,793 | $-6,442,033 |
| Diluted Average Shares | $19,571,880 | $13,414,314 | $9,817,980 | $8,293,005 |
| Basic Average Shares | $19,571,880 | $13,414,314 | $9,817,980 | $8,293,005 |
| Diluted NI Availto Com Stockholders | $-3,954,781 | $-7,687,317 | $-11,727,444 | $-6,457,939 |
| Other Special Charges | $-631,796 | $-213,648 | $248,110 | - |
| Impairment Of Capital Assets | $1,286,704 | $1,445,100 | $7,396,821 | $0 |
| Gain On Sale Of Security | $-4,357 | $-27,525 | $-16,491 | $-23,562 |
| Research And Development | $1,500 | $133,732 | $962,708 | $726,057 |
| Selling General And Administration | $3,116,751 | $2,262,620 | $2,835,219 | $5,252,619 |
| Other Gand A | $2,392,270 | $2,111,990 | $2,160,954 | $2,395,565 |
| Salaries And Wages | $302,033 | $150,630 | $499,967 | $1,137,253 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,920,122 | $-3,372,061 | $-773,532 | $779,900 |
| Total Assets | $1,300,764 | $113,478 | $865,564 | $8,503,584 |
| Total Non Current Assets | $0 | $0 | $151,035 | $7,629,097 |
| Current Assets | $1,300,764 | $113,478 | $714,529 | $874,487 |
| Prepaid Assets | $653,037 | $24,976 | $360,630 | $148,466 |
| Receivables | $435,921 | $87,525 | $212,001 | $132,906 |
| Other Receivables | $32,488 | - | - | - |
| Taxes Receivable | $203,433 | $87,525 | $45,291 | $48,961 |
| Cash Cash Equivalents And Short Term Investments | $211,806 | $977 | $141,898 | $593,115 |
| Cash And Cash Equivalents | $211,806 | $977 | $141,898 | $593,115 |
| Cash Financial | $211,806 | $977 | $141,898 | $593,115 |
| Non Current Note Receivables | - | $0 | $151,035 | $232,276 |
| Loans Receivable | - | $0 | $166,710 | $83,945 |
| Goodwill And Other Intangible Assets | - | - | $0 | $7,396,821 |
| Other Intangible Assets | - | - | - | $7,396,821 |
| Debt | ||||
| Total Debt | $68,080 | - | - | - |
| Current Debt And Capital Lease Obligation | $68,080 | - | - | - |
| Current Debt | $68,080 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,220,886 | $3,485,539 | $1,639,096 | $326,863 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $3,220,886 | $3,485,539 | $1,639,096 | $326,863 |
| Current Notes Payable | $68,080 | $0 | - | - |
| Payables And Accrued Expenses | $3,152,806 | $3,485,539 | $1,639,096 | $326,863 |
| Payables | $2,455,856 | $3,413,524 | $1,518,197 | $288,748 |
| Accounts Payable | $1,556,860 | $2,655,875 | $1,312,736 | $216,465 |
| Equity | ||||
| Common Stock Equity | $-1,920,122 | $-3,372,061 | $-773,532 | $8,176,721 |
| Total Equity Gross Minority Interest | $-1,920,122 | $-3,372,061 | $-773,532 | $8,176,721 |
| Stockholders Equity | $-1,920,122 | $-3,372,061 | $-773,532 | $8,176,721 |
| Other Equity Interest | $22,667 | - | - | - |
| Gains Losses Not Affecting Retained Earnings | $2,263,208 | $1,930,707 | $1,782,760 | $1,441,388 |
| Other Equity Adjustments | $2,263,208 | $1,930,707 | $1,782,760 | $1,441,388 |
| Retained Earnings | $-31,250,384 | $-27,295,603 | $-19,608,286 | $-8,022,452 |
| Other | ||||
| Ordinary Shares Number | $26,205,849 | $14,511,182 | $10,881,263 | $9,218,696 |
| Share Issued | $26,205,849 | $14,511,182 | $10,881,263 | $9,218,696 |
| Tangible Book Value | $-1,920,122 | $-3,372,061 | $-773,532 | $779,900 |
| Invested Capital | $-1,852,042 | $-3,372,061 | $-773,532 | $8,176,721 |
| Working Capital | $-1,920,122 | $-3,372,061 | $-924,567 | $547,624 |
| Total Capitalization | $-1,920,122 | $-3,372,061 | $-773,532 | $8,176,721 |
| Capital Stock | $27,044,387 | $21,992,835 | $17,051,994 | $14,757,785 |
| Common Stock | $27,044,387 | $21,992,835 | $17,051,994 | $14,757,785 |
| Current Accrued Expenses | $696,950 | $72,015 | $120,899 | $38,115 |
| Dueto Related Parties Current | $898,996 | $757,649 | $205,461 | $72,283 |
| Duefrom Related Parties Current | $200,000 | $0 | - | - |
| Treasury Shares Number | - | $0 | - | - |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,918,601 | $-1,054,849 | $-1,574,609 | $-5,294,426 |
| Operating Activities | ||||
| Operating Cash Flow | $-1,862,237 | $-1,054,849 | $-1,574,609 | $-5,294,426 |
| Cash Flow From Continuing Operating Activities | $-1,862,237 | $-1,054,849 | $-1,574,609 | $-5,294,426 |
| Operating Gains Losses | $449,865 | $-229,953 | $248,110 | $5,662 |
| Cash From Discontinued Operating Activities | - | - | - | $0 |
| Investing Activities | ||||
| Capital Expenditure | $-1,056,364 | - | - | - |
| Investing Cash Flow | $-1,056,364 | $0 | - | - |
| Cash Flow From Continuing Investing Activities | $-1,056,364 | $0 | - | - |
| Cash From Discontinued Investing Activities | - | - | - | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $3,160,512 | $917,100 | $1,108,245 | $3,060,234 |
| Financing Cash Flow | $3,127,083 | $917,100 | $1,108,245 | $3,438,986 |
| Cash Flow From Continuing Financing Activities | $3,127,083 | $917,100 | $1,108,245 | $3,438,986 |
| Net Common Stock Issuance | $3,160,512 | $917,100 | $1,108,245 | $3,060,234 |
| Common Stock Issuance | $3,160,512 | $917,100 | $1,108,245 | $3,060,234 |
| Other | ||||
| Repayment Of Debt | $-33,429 | $0 | $0 | $-369,700 |
| End Cash Position | $211,806 | $977 | $141,898 | $593,115 |
| Beginning Cash Position | $977 | $141,898 | $593,115 | $2,423,095 |
| Effect Of Exchange Rate Changes | $2,347 | $-3,172 | $15,147 | $25,460 |
| Changes In Cash | $208,482 | $-137,749 | $-466,364 | $-1,855,440 |
| Net Issuance Payments Of Debt | $-33,429 | $0 | $0 | $-369,700 |
| Net Short Term Debt Issuance | $-33,429 | $0 | - | - |
| Short Term Debt Payments | $-33,429 | $0 | - | - |
| Net Intangibles Purchase And Sale | $-1,056,364 | $0 | - | - |
| Purchase Of Intangibles | $-1,056,364 | $0 | - | - |
| Net PPE Purchase And Sale | $-1,056,364 | $0 | - | - |
| Purchase Of PPE | $-1,056,364 | $0 | - | - |
| Change In Working Capital | $53,942 | $2,189,039 | $1,903,708 | $-83,352 |
| Change In Payables And Accrued Expense | $830,457 | $2,352,747 | $2,111,402 | $-524,949 |
| Change In Payable | $830,457 | $2,352,747 | $2,111,402 | $-524,949 |
| Change In Account Payable | $689,110 | $1,800,559 | $1,978,224 | $-501,452 |
| Change In Prepaid Assets | $-628,119 | $-121,474 | $-211,364 | $442,242 |
| Change In Receivables | $-148,396 | $-42,234 | $3,670 | $-645 |
| Stock Based Compensation | $302,033 | $150,630 | $499,967 | $1,137,253 |
| Asset Impairment Charge | $1,286,704 | $1,445,100 | $7,396,821 | $0 |
| Net Foreign Currency Exchange Gain Loss | $2,275 | $-16,305 | $0 | $5,662 |
| Net Income From Continuing Operations | $-3,954,781 | $-7,687,317 | $-11,727,444 | $-6,457,939 |
| Other Non Cash Items | - | $3,077,652 | $104,229 | $103,950 |
| Proceeds From Stock Option Exercised | - | - | $0 | $748,452 |
| Net Long Term Debt Issuance | - | - | $0 | $-369,700 |
| Long Term Debt Payments | - | - | $0 | $-369,700 |
Fetched: 2026-02-02